← Back to Search

Telemedicine for Cancer-Related Depression and Pain

Phase 3

Waitlist Available

Research Sponsored by Indiana University Melvin and Bren Simon Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will compare telemedicine to standard care in treating patients with depression and/or pain caused by cancer.

Who is the study for?

This trial is for cancer patients experiencing moderate to severe depression (with a PHQ-9 score of 10 or higher) and/or pain (with a Brief Pain Inventory score of at least 6), not caused by treatments known for inducing depression. Participants must have a life expectancy over 6 months, speak English, and not be pregnant or suffering from cognitive impairments, schizophrenia, psychosis, or pursuing disability claims.Check my eligibility

What is being tested?

The study is examining the effectiveness of telemedicine versus standard care in managing depression and pain in cancer patients. It's designed as a phase III randomized clinical trial where participants are randomly assigned to receive either remote medical consultations (telemedicine) or traditional face-to-face healthcare services.See study design

What are the potential side effects?

Since this trial compares telemedicine with standard care rather than medication interventions, side effects are not typical as with drug trials. However, there may be differences in satisfaction or psychological impact between the two methods.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Compare efficacy of 3-component model telemedicine intervention to standard care in terms of depression and pain at baseline and 1, 3, 6, and 12 months

Secondary outcome measures

Cost-effectiveness of care at baseline and 1, 3, 6, and 12 months

Health-related quality of life at baseline and 1, 3, 6, and 12 months

Treatment satisfaction at baseline and 1, 3, 6, and 12 months

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Indiana University Melvin and Bren Simon Cancer CenterLead Sponsor

5 Previous Clinical Trials

208 Total Patients Enrolled

National Cancer Institute (NCI)NIH

13,658 Previous Clinical Trials

40,924,009 Total Patients Enrolled

97 Trials studying Pain

17,222 Patients Enrolled for Pain

Kurt Kroenke, MDStudy ChairRegenstrief Institute, Incorporated

5 Previous Clinical Trials

1,381 Total Patients Enrolled

4 Trials studying Pain

1,346 Patients Enrolled for Pain

Media Library

Standard Care Clinical Trial Eligibility Overview. Trial Name: NCT00313573 — Phase 3

Pain Clinical Trial 2023: Standard Care Highlights & Side Effects. Trial Name: NCT00313573 — Phase 3

Standard Care 2023 Treatment Timeline for Medical Study. Trial Name: NCT00313573 — Phase 3

Pain Patient Testimony for trial: Trial Name: NCT00313573 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this experimental program?

"Unfortunately, this study is not actively recruiting patients according to the clinicaltrials.gov website. The original posting was on February 1st, 2006 with the last update taking place on September 19th, 2013. There are, however, 1,729 other clinical trials that are currently looking for participants."

Answered by AI

What are the odds of experiencing adverse effects from this medication?

"The safety of this treatment was rated a 3 by our team at Power. This is due to the fact that this is a Phase 3 trial, thus there is both some efficacy data as well as multiple rounds of safety data."

Answered by AI